Why the study?
Does the selective NLRP3-inflammasome inhibitor MCC950 reduce infarct size and preserve cardiac function in a pig model of myocardial infarction?
Does the selective NLRP3-inflammasome inhibitor MCC950 reduce infarct size and preserve cardiac function in a pig model of myocardial infarction?
In a translational pig model of myocardial infarction, the NLRP3-inflammasome inhibitor MCC950 successfully reduced infarct size and preserved cardiac function, indicating potential therapeutic value for acute MI.
Does not support clinical use in MI; leaves open translation of NLRP3 inhibition to human trials.
NLRP3-inflammasome inhibition reduces infarct size and preserves cardiac function in a randomized, blinded translational large animal MI model. Hence, NLRP3-inflammasome inhibition may have therapeutic potential in acute MI patients.
No takes yet. Share an insight, caveat, or question.
Hout et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: